Cut‐off value of nuchal translucency as indication for chromosomal microarray analysis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Ultrasound in Obstetrics and Gynecology

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/uog.17421PMID 28133835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noninvasive prenatal screening or advanced diagnostic testing: caveat emptor.

  2016cited by this paper
• The use of chromosomal microarray for prenatal diagnosis.

  2016cited by this paper
• Genetics: update on prenatal screening and diagnosis.

  2015cited by this paper
• Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta‐analysis

  2015cited by this paper
• Chromosomal microarray in fetuses with increased nuchal translucency

  2015cited by this paper
• High‐resolution chromosomal microarrays in prenatal diagnosis significantly increase diagnostic power

  2014cited by this paper
• Additional value of prenatal genomic array testing in fetuses with isolated structural ultrasound abnormalities and a normal karyotype: a systematic review of the literature

  2014cited by this paper
• Increased nuchal translucency with normal karyotype and anomaly scan: what next?

  2014cited by this paper
• Is high fetal nuchal translucency associated with submicroscopic chromosomal abnormalities on array CGH?

  2014cited by this paper
• Prenatal diagnosis using combined quantitative fluorescent polymerase chain reaction and array comparative genomic hybridization analysis as a first‐line test: results from over 1000 consecutive cases

  2013cited by this paper
• Prenatal diagnosis using array-CGH: a French experience.

  2013cited by this paper
• The clinical utility of microarray technologies applied to prenatal cytogenetics in the presence of a normal conventional karyotype: a review of the literature

  2013cited by this paper
• Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta‐analysis

  2013cited by this paper
• Chromosomal microarray versus karyotyping for prenatal diagnosis.

  2012cited by this paper
• Non‐targeted whole genome 250K SNP array analysis as replacement for karyotyping in fetuses with structural ultrasound anomalies: evaluation of a one‐year experience

  2012cited by this paper
• Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound

  2012cited by this paper
• Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype

  2011cited by this paper
• Testing for 22q11 microdeletion in 146 fetuses with nuchal translucency above the 99th percentile and a normal karyotype

  2008cited by this paper
• Nuchal Translucency and First Trimester Risk Assessment: A Systematic Review

  2007cited by this paper
• Increased nuchal translucency with normal karyotype.

  2005cited by this paper
• Pathophysiology of increased nuchal translucency: a review of the literature.

  2003cited by this paper
• Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation

  1998cited by this paper
• UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.

  1998cited by this paper
• Ultrasonographically detectable markers of fetal chromosomal abnormalities.

  1992cited by this paper

• Diagnostic Value of Karyotype, Microarray, RASopathy Gene Testing and Ultrasound in Fetuses with Nuchal Translucency 3.0-3.4 mm: A Single-Center Cohort Retrospective Study.

  2026cites this paper
• Impact of a new image enhancement technology on the nuchal translucency thickness

  2025influential citation
• Outcomes associated with fetal nuchal translucency between 3.0 and 3.4 mm in the first trimester

  2025influential citation
• How Useful is Nuchal Translucency in Detecting Chromosomal Abnormalities Missed by Genome‐Wide NIPT and What Measurement Threshold Should Be Used?

  2025cites this paper
• Copy number variants in fetuses with isolated and non-isolated increased nuchal translucency detected by chromosomal microarray analysis

  2025cites this paper
• Developing a transfer learning model for the prediction of Down syndrome from first-trimester ultrasound images.

  2025cites this paper
• Implementation of the new S2e guideline “first-trimester diagnostics and therapy @ 11–13 + 6 weeks of pregnancy”: a survey in outpatient practices

  2025influential citation
• Evaluating the clinical utility and strategy of whole exome sequencing testing for fetuses with increased nuchal translucency.

  2025cites this paper
• Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study

  2024influential citation
• Array Comparative Genomic Hybridization (aCGH) Results among Patients Referred to Invasive Prenatal Testing after First-Trimester Screening: A Comprehensive Cohort Study

  2024influential citation
• Selection of prenatal screening with nuchal translucency > 95th centile and below 99th centile: a 4-year observational study with real-world data

  2024cites this paper
• Ultrasonographic Fetal Nuchal Translucency Measurements and Cytogenetic Outcomes

  2024cites this paper
• Clinical value of screening prenatal ultrasound combined with chromosomal microarrays in prenatal diagnosis of chromosomal abnormalities

  2024cites this paper
• Comparison of Chromosomal Microarray Analysis and Noninvasive Prenatal Testing in Pregnant Women with Fetal Ultrasonic Soft Markers

  2024cites this paper
• The Impact of Isolated Increased Nuchal Translucency ≥95th Centile on Perinatal Outcome: A Prospective Cohort Study from a North Indian Genetic Center

  2023cites this paper
• Predicting the risk of Turner syndrome based on ultrasonographic markers in the first trimester of pregnancy

  2023cites this paper
• Empfehlungen der DEGUM zu diagnostischen Punktionen in der Pränatalmedizin DEGUM Recommendations on Diagnostic Puncture in Prenatal Medicine

  2023cites this paper
• Identification of Fetuses at Increased Risk of Trisomies in the First Trimester Using Axial Planes

  2023influential citation
• Prenatal diagnosis and early childhood outcome of fetuses with extremely large nuchal translucency

  2023cites this paper
• When NIPT meets WES, prenatal diagnosticians face the dilemma: genetic etiological analysis of 2,328 cases of NT thickening and follow-up of pregnancy outcomes

  2023cites this paper
• The clinical impact of the first‐trimester nuchal translucency between the 95th–99th percentiles

  2023cites this paper
• Chromosomal microarray analysis versus noninvasive prenatal testing in fetuses with increased nuchal translucency

  2022cites this paper
• Empfehlungen der DEGUM zu diagnostischen Punktionen in der Pränatalmedizin

  2022cites this paper
• Molecular Approaches in Fetal Malformations, Dynamic Anomalies and Soft Markers: Diagnostic Rates and Challenges—Systematic Review of the Literature and Meta-Analysis

  2022cites this paper
• Antenatal screening for chromosomal abnormalities

  2022cites this paper
• Outcome of pregnancies with first‐trimester increased nuchal translucency and cystic hygroma in a tertiary maternity hospital in United Arab Emirates

  2022cites this paper
• Array study in fetuses with nuchal translucency above the 95th percentile: a 4-year observational single-centre study

  2022cites this paper
• A Pain in the Neck: Lessons Learnt from Genetic Testing in Fetuses Detected with Nuchal Fluid Collections, Increased Nuchal Translucency versus Cystic Hygroma—Systematic Review of the Literature, Meta-Analysis and Case Series

  2022cites this paper
• Application of expanded noninvasive prenatal test in prenatal diagnosis of fetuses with increased nuchal translucency

  2021cites this paper
• Noninvasive prenatal testing for assessing foetal sex chromosome aneuploidy: a retrospective study of 45,773 cases

  2021cites this paper
• United States' experience in nuchal translucency measurement: variation according to provider characteristics in over five million ultrasound examinations

  2021cites this paper
• Chances and Challenges of New Genetic Screening Technologies (NIPT) in Prenatal Medicine from a Clinical Perspective: A Narrative Review

  2021cites this paper
• Re-examining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study.

  2021cites this paper
• Prenatal Invasive Testing at a Tertiary Referral Center in India: A Report of 433 Cases Under a Single Operator

  2021cites this paper
• Increased nuchal translucency after low‐risk noninvasive prenatal testing: What should we tell prospective parents?

  2021influential citation
• Combined Application of Chromosome Karyotype and Microarray Analysis in Fetus With Increased Nuchal Translucency

  2021cites this paper
• 14 Weeks Gestational

  2020cites this paper
• ACR Appropriateness Criteria® Nuchal Translucency Evaluation at 11 to 14 Weeks of Gestation.

  2020cites this paper
• Clinical application of chromosomal microarray for pathogenic genomic imbalance in fetuses with increased nuchal translucency but normal karyotype

  2020cites this paper
• Exome Sequencing for Prenatal Diagnosis in Nonimmune Hydrops Fetalis.

  2020cites this paper
• Abnormal nuchal translucency: residual risk with normal cell-free DNA screening

  2020cites this paper
• Application of chromosomal microarray in fetuses with increased nuchal translucency

  2020cites this paper
• Distribution of nuchal translucency thickness at 11 to 14 weeks of gestation in a normal Turkish population

  2020cites this paper
• Risk of Clinically Significant Chromosomal Microarray Analysis Findings in Fetuses With Nuchal Translucency From 3.0 mm Through 3.4 mm.

  2020cites this paper
• Nuchal Translucency Evaluation at 11 to 14 Weeks Gestational Age

  2020cites this paper
• Nuchal translucency of 3.0‐3.4 mm an indication for NIPT or microarray? Cohort analysis and literature review

  2020cites this paper
• Fetal nuchal translucency: is there an association with birthweight and neonatal wellbeing?

  2019cites this paper
• Reply

  2019cites this paper
• Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?

  2019cites this paper
• Pränataldiagnostik – klassische Analytik mittels Chorionzottenbiopsie und Amniocentese

  2019cites this paper
• Prenatal Diagnostic Value of Chromosomal Microarray in Fetuses with Nuchal Translucency Greater than 2.5 mm

  2019cites this paper
• Clinical application of chromosomal microarray analysis in fetuses with increased nuchal translucency and normal karyotype

  2019cites this paper
• Serum and Ultrasound Based Screening Tests for Aneuploidy

  2019cites this paper
• What would be missed in the first trimester if nuchal translucency measurement is replaced by cell free DNA foetal aneuploidy screening?

  2018cites this paper
• DEGUM, ÖGUM, SGUM and FMF Germany Recommendations for the Implementation of First-Trimester Screening, Detailed Ultrasound, Cell-Free DNA Screening and Diagnostic Procedures.

  2018cites this paper
• Chromosomal Microarray Analysis Results From Pregnancies With Various Ultrasonographic Anomalies.

  2018cites this paper
• False-Positive Rate in First-Trimester Screening Based on Ultrasound and Cell-Free DNA versus First-Trimester Combined Screening with Additional Ultrasound Markers

  2018cites this paper
• First‐trimester risk assessment based on ultrasound and cell‐free DNA vs combined screening: a randomized controlled trial

  2018cites this paper
• Das fetale Profil im ersten Trimenon – mehr als nur NT

  2017cites this paper
• Re: Cut‐off value of nuchal translucency as indication for chromosomal microarray analysis. I. Maya, S. Yacobson, S. Kahana, J. Yeshaya, T. Tenne, I. Agmon‐Fishman, L. Cohen‐Vig, M. Shohat, L. Basel‐Vanagaite and R. Sharony. Ultrasound Obstet Gynecol 2017; 50: 332–335.

  2017cites this paper
• Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities

  2017cites this paper